🇺🇸 FDA
Patent

US 10071101

Use of cinnabarinic acid as a modulator of immune response in autoimmune disorders

granted A61KA61K31/538A61P

Quick answer

US patent 10071101 (Use of cinnabarinic acid as a modulator of immune response in autoimmune disorders) held by The Regents of the University of California expires Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Sep 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 06 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61K, A61K31/538, A61P, A61P1/16, A61P17/00